stockrow
Friday 6 November 2026
Export VRTX’s income statement to Excel — free account
Vertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024.
- Revenue
- +11.9%
- EPS
- −39.2%
- Free cash flow
- −52.1%
Quarter to September 2026, against a year earlier
547.43
4.93
+0.91%
Follow VRTX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
29.31 | 26.25 | 28.66 | 33.37 |
P/S ratio |
9.66 | 9.29 | 10.01 | 10.23 | |
P/FCF ratio |
36.30 | 30.58 | 33.20 | 41.39 | |
P/Operating CF |
232.78 | 79.45 | 111.98 | 206.08 | |
P/B ratio |
6.21 | 5.86 | 6.22 | 6.34 | |
Price to Tangible BV |
6.76 | 6.35 | 6.72 | 13.30 | |
EV/Sales |
9.14 | 8.73 | 9.42 | 10.04 | |
EV/EBITDA |
25.03 | 21.77 | 23.72 | 28.63 | |
EV/Operating CF |
30.22 | 25.15 | 27.62 | 35.19 | |
EV/FCF |
34.36 | 28.74 | 31.24 | 40.60 | |
Quick Ratio |
2.24 | 2.38 | 2.54 | 1.72 | |
Current Ratio |
2.90 | 3.02 | 3.19 | 2.34 | |
Net Debt/EBITDA |
(5.24) | (6.07) | (6.02) | (3.59) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 10.68% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.17 | |
Asset Turnover |
0.50 | 0.50 | 0.49 | 0.45 | |
Operating CF/Net income |
0.42 | 1.38 | 1.02 | 0.98 | |
Capex/Depreciation |
(2.68) | (2.39) | (1.99) | (1.41) | |
Interest Coverage |
120.59 | — | — | 19.80 | |
Research and Development Expense of Revenue |
30.52% | 32.19% | 29.81% | 38.38% | |
Selling, General and Administrative Expense of Revenue |
15.27% | 16.53% | 17.46% | 24.53% | |
Intangible Assets out of Total Assets |
0.06 | 0.06 | 0.05 | 0.33 | |
Share Based Compensation of Revenue |
4.94% | 5.57% | 5.11% | 5.07% | |
Graham Net Nets |
0.04 | 0.04 | 0.04 | 0.00 | |
Graham Number |
159.40 | 170.77 | 176.41 | 170.52 | |
Earnings Yield |
3.41% | 3.81% | 3.49% | 3.00% | |
Free Cash Flow Yield |
2.76% | 3.27% | 3.01% | 2.42% | |
Revenue per Share |
12.48 | 11.75 | 13.14 | 13.57 | |
Operating CF per Share |
1.95 | 5.62 | 4.44 | 2.54 | |
Capex per Share |
(0.58) | (0.52) | (0.44) | (0.38) | |
Free Cash Flow per Share |
1.36 | 5.10 | 3.99 | 2.15 | |
Cash per Share |
25.84 | 28.52 | 30.95 | 24.87 | |
Shareholders Equity per Share |
73.00 | 76.20 | 79.81 | 82.48 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
73.00 | 76.20 | 79.81 | 82.48 | |
Free Cash Flow |
348.60 | 1,294.70 | 1,013.20 | 545.80 | |
Working Capital |
7,339.80 | 7,849.70 | 8,605.80 | 6,686.00 | |
Capital Expenditures |
(149.40) | (133.40) | (112.20) | (97.30) | |
Net Current Asset Value |
4,223.80 | 4,607.80 | 5,368.30 | (142.60) | |
EV/EBIT |
26.29 | 22.78 | 24.82 | 30.21 | |
Capex to Sales |
0.05 | 0.04 | 0.03 | 0.03 | |
Price to Operating Income |
27.78 | 24.24 | 26.38 | 30.79 | |
| Other line items | |||||
Average Receivables |
1,831.10 | 1,900.60 | 2,013.90 | 2,128.70 | |
Average Payables |
437.35 | 467.15 | 435.90 | 446.45 | |
Average Inventory |
1,446.10 | 1,563.20 | 1,632.20 | 1,936.05 | |
Average Assets |
24,088.10 | 24,682.45 | 25,730.00 | 28,799.30 | |
Average Common Equity |
17,537.70 | 17,929.10 | 18,711.65 | 19,113.10 |
Columns are period end dates · fundamentals updated 5 Nov 2026